ODN/Pam2 - Pulmotect

Drug Profile

ODN/Pam2 - Pulmotect

Alternative Names: ODN-M362/Pam2CSK4; Pam2/ODN; Pam2CSK4/ODN-M362; PUL-042

Latest Information Update: 13 Oct 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Pulmotect
  • Class Antisense oligonucleotides; Lipopeptides
  • Mechanism of Action Immunostimulants; Toll-like receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Pneumocystis pneumonia

Most Recent Events

  • 04 Apr 2017 Pulmotect plans a phase I trial for Haematologic malignancies in USA (NCT03097796)
  • 28 Feb 2014 Phase-I clinical trials in Pneumocystis pneumonia (prevention, in volunteers) in USA (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top